07/26/11 - Rosetta Genomics (NASDAQ: ROSGD), a leading developer and provider of microRNA-based molecular diagnostic tests, announced preliminary data from a study it conducted in order to identify a microRNA signature in blood for congestive heart failure (HF) syndrome and to assess the feasibility to develop a minimally-invasive, microRNA-based stratification test for HF.
Demographic and clinical status of HF patients in combination with indices of cardiac and renal function can identify a large proportion of high risk patients, however, risk stratification based on these factors alone remains imprecise, with some high risk patients not recognized and others inappropriately marked as high risk. Early identification of patients at higher risk for adverse events could lead to earlier intervention that could potentially improve outcomes... Rosetta Genomics' Press Release -
